Commitments and Contingencies (Details) - USD ($)								1 Months Ended										3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Oct. 12, 2022	Jan. 27, 2022	Jun. 01, 2021	Apr. 12, 2021	Jan. 05, 2021	Aug. 31, 2023	Feb. 28, 2023	Oct. 25, 2022	Jun. 22, 2022	Feb. 28, 2022	Jan. 27, 2022	Dec. 29, 2021	Apr. 30, 2021	Feb. 17, 2021	Apr. 17, 2020	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2021	Oct. 31, 2023	Oct. 31, 2022	Oct. 13, 2022	Aug. 31, 2022	Jul. 31, 2022	Nov. 30, 2021	Sep. 01, 2021
Commitments and Contingencies (Details) [Line Items]
Research and development expenses																		$ 174,495	$ 375,795	$ 508,127	$ 651,750
License agreement expire																				15 years
percentage of sublicense income receivable																				25.00%
Prepaid expense and other current assets	$ 79,909																	$ 79,909		$ 79,909		$ 135,894
Sales of licensed products percentage																				5.00%
Sales																				$ 50,000,000
Convertible preferred stock (in Shares)	4,280																	4,280		4,280
Deferred revenue current	$ 72,102																	$ 72,102		$ 72,102		72,102
Deferred revenue long term	811,706																	811,706		811,706		865,782
Upfront license fees																				1,900,000
Installments payable	81,474																	81,474		81,474
Sponsored study agreement																				40,737
payment to companies																							$ 40,737
Research and development expense																				13,944		33,252	40,737
Sublicense amount paid					$ 342,850
Remaining amount due	60,570																	60,570		60,570
Accounts payable and accrued expenses	92,095																	92,095		92,095		92,095
Cash paid	330,825							$ 100,000										330,825		330,825						$ 430,825
Accounts payable	143,607																	143,607		$ 143,607
Percentage of estimate research																				90.00%
Total fee										$ 41,306
Payment of university																				$ 5,000
Professional fees																		338,164	402,190	1,273,729	846,617
Minimum [Member]
Commitments and Contingencies (Details) [Line Items]
Base salary	120,000
Maximum [Member]
Commitments and Contingencies (Details) [Line Items]
Base salary	180,000
License [Member]
Commitments and Contingencies (Details) [Line Items]
Paying fee																				$ 3,750	3,750
Series M Convertible Preferred [Member]
Commitments and Contingencies (Details) [Line Items]
Convertible preferred stock (in Shares)						500
Board of Directors [Member]
Commitments and Contingencies (Details) [Line Items]
Vested shares (in Shares)														30,224
Risk free interest rate														0.75%
Expected term														2 years
Expected volatility														0.00%
First Payment [Member]
Commitments and Contingencies (Details) [Line Items]
Cash paid																													$ 430,825
Second Payment [Member]
Commitments and Contingencies (Details) [Line Items]
Cash paid																												$ 430,825
Sublicense Agreement [Member]
Commitments and Contingencies (Details) [Line Items]
Prepaid expense and other current assets																						838
Prepaid expenses non-current																						10,196
Sublicense income, percentage															25.00%
Sublicense agreement amount paid															$ 12,500
JV Agreement [Member]
Commitments and Contingencies (Details) [Line Items]
Joint venture agreement description.																				Pursuant to the terms of the JV Agreement, (A) the Company shall contribute (1) $225,000 and (2) its expertise and the expertise of its science advisory board and (B) ZTI shall contribute (1) certain rights to certain of its patented technology as set forth in the JV Agreement, (2) a license to the know-how and trade secrets with respect to its Z-pod™ technology for the loading and release of ketamine, (3) ketamine to be used for clinical purposes, (4) reasonable use of its facilities and permits and (5) its expertise and know-how. Pursuant to the JV Agreement, 51% of the interest in the Joint Venture shall initially be owned by the Company and 49% of the interest in the Joint Venture shall initially be owned by ZTI, subject to adjustment in the event of additional contributions by either party. Notwithstanding the foregoing, in no event shall either party own more than 60% of the interest in the Joint Venture.
Sponsored Study Agreement [Member]
Commitments and Contingencies (Details) [Line Items]
Installments payable	40,737																	40,737		$ 40,737
Sponsored Research Agreement with The Regents of the University of California [Member]
Commitments and Contingencies (Details) [Line Items]
Prepaid expense and other current assets	0																	0		0		10,857
Prepaid expenses																						181,710	$ 100,570
Sponsored Research Agreement with Columbia University [Member]
Commitments and Contingencies (Details) [Line Items]
Research and development expense																				$ 71,427	128,855
Columbia University [Member]
Commitments and Contingencies (Details) [Line Items]
Sponsored research agreement, description																				On October 1, 2021, the Company entered into a sponsored research agreement with Columbia University pursuant to which the Company has been granted an option to license certain assets currently under development, including assets related to the potential treatment of patients suffering from Alzheimer’s disease. The term of the option will commence on the effective date of this agreement and will expire upon the earlier of (i) 90 days after the date of the Company’s receipt of a final research report for each specific research proposal as defined in the agreement or (ii) termination of the research. If the Company elects to exercise the option, both parties will commence negotiation of a license agreement and will execute a license agreement no later than 3 months after the date of the exercise of the option. Columbia University and the Company will work towards developing a therapeutic treatment for patients suffering from Alzheimer’s disease to post-traumatic stress disorder. During a one-year period from the date of this agreement, the Company shall pay a total of $1,436,082 to Columbia University for the support of the research according to the payment schedule as follows: (i) 30% at signing, (ii) 30% at four and half months after the start of the project, (iii) 30% at nine months after the start of the project and, (iv)10% at completion of the project.
Eric Weisblum [Member]
Commitments and Contingencies (Details) [Line Items]
Base salary			$ 350,000														$ 120,000
Vested shares (in Shares)																	152,619
Signing bonus			100,000
Eric Weisblum [Member] | Board of Directors [Member]
Commitments and Contingencies (Details) [Line Items]
Annual bonus			350,000
Mr. Weisblum [Member]
Commitments and Contingencies (Details) [Line Items]
Annual bonus	200,000		200,000															200,000		$ 200,000
Daniel Ryweck [Member]
Commitments and Contingencies (Details) [Line Items]
Base salary			$ 60,000																	$ 42,000
Dr. James Kuo [Member]
Commitments and Contingencies (Details) [Line Items]
Base salary				$ 30,000
Share granted (in Shares)													16,000
Exercisable per share (in Dollars per share)				$ 10									$ 10
Expire date													Jan. 31, 2032
Stock options (in Shares)				6,000									6,000
Vests (in Shares)																									5,000
Stock option (in Shares)																				16,000
Fair value of stock option																				$ 94,915
Risk free interest rate																				1.18%
Expected dividend yield																				0.00%
Expected term																				2 years
Expected volatility																				117.00%
Fair value of the unvested stock option																				$ 94,915
Amortized deferred compensation	12,711																	12,711	$ 73,257	12,711	73,257
Deferred compensation balance																				1,414		14,125
Dr. James Kuo [Member] | Forecast [Member]
Commitments and Contingencies (Details) [Line Items]
Vests (in Shares)																								5,000
University of Maryland Baltimore [Member]
Commitments and Contingencies (Details) [Line Items]
Paying fee		$ 1,000
Additional license fee									$ 2,500
Extension Fee								2,500
University of Maryland Baltimore [Member] | Third Amendment [Member]
Commitments and Contingencies (Details) [Line Items]
Research and development expenses											$ 2,500
University of Maryland Baltimore [Member] | Extension fee [Member]
Commitments and Contingencies (Details) [Line Items]
Paying fee									1,000
University of Maryland Baltimore [Member] | License [Member]
Commitments and Contingencies (Details) [Line Items]
Paying fee								$ 2,500	$ 1,000
Master Lincense Agreement [Member]
Commitments and Contingencies (Details) [Line Items]
Paying fee												$ 50,000								$ 629
Commercial sale term																				10 years
percentage of sublicense income receivable																				15.00%
Due amount																				$ 25,000
Paid amount												$ 50,000
Term year												15 years
Prepaid expense and other current assets	5,000																	5,000		5,000		5,000
Prepaid expenses non-current	56,875																	56,875		$ 56,875		60,625
Sales of licensed products percentage																				3.00%
Sales																				$ 50,000,000
Master Lincense Agreement [Member] | License [Member]
Commitments and Contingencies (Details) [Line Items]
Paying fee																$ 25,000				75,000	629
Master Lincense Agreement [Member] | Sublicense Agreement [Member]
Commitments and Contingencies (Details) [Line Items]
Prepaid expense and other current assets	838																	838		838
Prepaid expenses non-current	9,567																	9,567		9,567
Customer Patent License Agreement with Aikido Pharma Inc [Member]
Commitments and Contingencies (Details) [Line Items]
Non-refundable cash payment							$ 500,000													$ 500,000
Net sale percentage																				2.00%
Licensor share (in Shares)							500													500
Aggregate of converted shares (in Shares)							625,000													625,000
Revenue term							15 years													15 years
Common stock shares (in Shares)						625,000
Per share (in Dollars per share)						$ 0.85
Trading price						$ 531,250
Equity investment						531,250
Deferred revenue	1,031,250					$ 531,250												1,031,250		$ 1,031,250
Cash received	500,000																	500,000		500,000
Securities received	531,250																	531,250		531,250
Recognized revenues																				51,562	51,562
Deferred revenue current	68,750																	68,750		68,750		68,750
Deferred revenue long term	773,438																	773,438		$ 773,438		825,000
Consideration fee payable percentage																				110.00%
Customer Sublicense Agreement with Aikido Pharma Inc [Member]
Commitments and Contingencies (Details) [Line Items]
Recognized revenues																				$ 2,514	2,514
Deferred revenue current	3,352																	3,352		3,352		3,352
Deferred revenue long term	38,268																	38,268		38,268		40,782
Upfront license fees															$ 50,000					$ 50,000
First commercial sale																				10 years
Agreement shall expire																				15 years
Sponsored Research Agreement with University of Maryland, Baltimore [Member]
Commitments and Contingencies (Details) [Line Items]
Prepaid expense and other current assets																											$ 92,095			$ 92,095
Research and development expense																				$ 0	92,095
Sponsored Research Agreement with The Regents of the University of California [Member]
Commitments and Contingencies (Details) [Line Items]
Research and development expense																				287,218	215,412
Sponsored Research Agreement with Columbia University [Member]
Commitments and Contingencies (Details) [Line Items]
Prepaid expense and other current assets	0																	0		$ 0		143,607
Accounts payable and accrued expenses																						20,134
Percentage of estimate research																				90.00%
Research Agreement with Reprocell [Member]
Commitments and Contingencies (Details) [Line Items]
Research and development expense																				$ 135,538	215,388
Accounts payable and accrued expenses	$ 0																	$ 0		0
Prepaid expense																						$ 21,172
Amended Service Agreement [Member]
Commitments and Contingencies (Details) [Line Items]
Professional fees																				$ 15,000	$ 15,000